News | 13 September 2021
Zydus Cadila seeks approval for a two-dose ZyCoV-D Covid-19 vaccine
The three-dose vaccine approved for EUA contains 2mg for each dose, whereas the two-dose plan will have 3mg in each dose.
The three-dose vaccine approved for EUA contains 2mg for each dose, whereas the two-dose plan will have 3mg in each dose.
One batch has 11.4 million units of Naproxen tablets out of which 0.9 million units that were released into the market were recalled
The tracker gives week by week coverage of the first and second dose of vaccine and also their effectiveness
.jpg)
The much-awaited drone delivery trials for the delivery of medicines and vaccines will be held in Vikarabad, Hyderabad from 9th September till 17th October.
The company plans to enter the formulation business in January 2022. It has also opened a branch in Hyderabad to trade pharmaceutical chemicals
A long waiting period for critical equipment and a 50% hike in the cost of APIs imported from China are among the immediate challenges
The World Health Organisation (WHO), has felt the need to conduct this training to build local capacities in poor countries to bridge the gap and enhance local production
The company’s RenovoCath Delivery System designed for targeted treatment of solid tumours
Labetalol hydrochloride injection USP is indicated for the control of blood pressure in severe hypertension.
Ind-Ra expects IPM revenue to grow over 12% YoY in FY22
The batch will be distributed in India through a partner of RDIF and Panacea Biotec - Dr. Reddy's Laboratories
The study is being carried out by the platform VISION (Vaccine Immunology Studies – Indian Outbreak-response Network) which includes top public and private research institutes.
The DGTR has recommended US $ 3.2 per kg and US $ 3.55 per kg duty on imports
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
The agreement follows positive NICE recommendation and commits to deliver Leqvio (inclisiran) access via a population health management approach identifying eligible patients across England
The company has been sold to Shinshin Pharmaceuticals
At its meeting, the board also approved raising the company’s authorised share capital to Rs. 42.50 crores from Rs. 37.50 crores.
The drug has been granted permission by DCGI for emergency use as an adjunct therapy for Covid-19
The revenues and profits derived from the new subsidiary will be consolidated in the parent company
The powder is approved for the treatment of adjunct therapy in moderate to severe Covid-19 patients
Subscribe To Our Newsletter & Stay Updated
